Progression from Psoriasis to Psoriatic Arthritis

Save

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).

FINCH 1 Trial Filgotinib in Rheumatoid Arthritis

Save

The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).

Treatment of MIS-C COVID in Kids

Save

The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular co

Tofacitinib Efficacy in COVID-19 Pneumonia

Save

NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.

EULAR 2021 – Day 4 Report

Save

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Problems at the FDA

Save

"While the Food and Drug Administration decision on new drugs usually follows the recommendations of the advisory committee..."; this oft used proviso is used to either indicate a pending FDA decision or an FDA decision that is contrary to the recommendation of the advisory committee co

RheumNow Podcast - Best of EULAR 2021

Save

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Save

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

EULAR 2021 - Day 2 Podcasts

Save

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com

Listen by Clicking below:

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Save

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

Foot Pain Commonly Overlooked in RA

Save

Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.

Best Interventions for Gout Flares

Save

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Methotrexate Impairs COVID Vax Response

Save

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

Triple DMARD Therapy Bested by Biologics in Swedish Registry

Save

The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.

CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis

Save

A large prospective cohort study examined the comparative risks of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) and found that, methotrexate (MTX), abatacept (ABA) and TNF inhibitor (TNFi) use were associated with a decreased risk of CV events. 

Tocilizumab Augmented Efficacy in COVID-19 Pneumonia with High CRP

Save

JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.

Congress Slams AbbVie Over Price Hikes, 'Frivolous' Patents

Save

House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.